[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2623]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2622]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2621]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2627]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96378]], camposKey:2774-681X 2025-01-01 Así deciden los comités tumorales cómo tratar cada cáncer de forma personalizada00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=89236]], camposKey:1552-4868 2025-01-01 Genomics review of selective RET inhibitors sensitivity in thyroid cancer clinical trials00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=91612]], camposKey:1046-3976 2025-01-01 TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=91613]], camposKey:1661-6596 2025-01-01 The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96140]], camposKey:2059-7029 2024-01-01 Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96321]], camposKey:0008-5472 2023-01-01 CREBBP/EP300 disruption promotes tumor progression and confers synthetic lethality in anaplastic thyroid cancers00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96074]], camposKey:0923-7534 2023-01-01 Frequent TERT gains in metastatic papillary thyroid carcinoma.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96072]], camposKey:0923-7534 2021-01-01 A comprehensive study of the role of EIF1AX mutations in anaplastic thyroid carcinomas. Relationship with established mutational events, tumor progression and dedifferentiation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=96071]], camposKey:0008-5472 2020-01-01 Spatio-temporal geographical molecular mapping of primary Papillary Thyroid Carcinomas and paired distant metastases. Clinical relevance for monitoring and targeting tumor heterogeneity00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77895]], camposKey:0008-5472 2019-01-01 Spatio-temporal genetic heterogeneity and clonal evolution in advanced papillary thyroid carcinomas and matched distant metastases00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56002]], camposKey:0923-7534 2019-01-01 Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM00][][com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=3221]], com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=3067]]][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61628]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61628]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1267]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1282]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1281]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1267]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1282]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=1281]]][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcComissioAssessor[id=com.sigma.fs3.argos.domain.gpc.GpcComissioAssessorPK[ifcactivitat=COM, ifccomptador=1965]], com.sigma.fs3.argos.domain.gpc.GpcComissioAssessor[id=com.sigma.fs3.argos.domain.gpc.GpcComissioAssessorPK[ifcactivitat=COM, ifccomptador=1964]], com.sigma.fs3.argos.domain.gpc.GpcComissioAssessor[id=com.sigma.fs3.argos.domain.gpc.GpcComissioAssessorPK[ifcactivitat=COM, ifccomptador=1963]]][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7c061cb, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7d167645, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1173b47a, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@ba8b92e, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@fe24fa9, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@4108a44e, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@4dd40871, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@3fbb92c, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1ef931fd][][][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=5108]]][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=5108]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60953]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60953]]][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c6210], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c6214], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c620f], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c620e]][][][][][][][][]
